Introduction: This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC.
Introduction
Secondary MNNG HOS Transforming gene (MET) amplification is one of the mechanisms of resistance to EGFR tyrosine kinase inhibitor (TKI) treatment in patients with NSCLC having activating EGFR mutations. 1 Combination of EGFR TKIs and mesenchymal-epithelial transition (MET) inhibitors is a rational approach to potentially delay the emergence of resistance to EGFR TKIs in TKI-naive patients with EGFR-positive NSCLC or to overcome resistance in patients with EGFR-positive NSCLC who progress while receiving single-agent EGFR TKIs. Crizotinib is approved for the treatment of advanced anaplastic lymphoma kinase (ALK)-rearranged or ROS1-rearranged NSCLC, 2, 3 but it was initially developed as a MET inhibitor and has shown clinical activity in NSCLC that harbors MET amplification or MET exon 14 skipping alterations. [4] [5] [6] Herein we report the results from a phase I study combining crizotinib with erlotinib in patients with advanced nonsquamous NSCLC (NCT00965731).
Patients and Methods

Study Design and Eligibility Criteria
This was a single-arm phase I study of crizotinib plus erlotinib, to be followed by a planned randomized phase II portion comparing the efficacy of crizotinib plus erlotinib versus erlotinib alone in patients with chemotherapyrefractory locally advanced/metastatic nonsquamous NSCLC.
The primary end point was to determine the maximum tolerated dose (MTD) of the combination of crizotinib and erlotinib. Secondary end points included evaluating the effect of crizotinib on erlotinib pharmacokinetics (PK) (as crizotinib is a moderate cytochrome P450 family 3 subfamily A member 4 [CYP3A4] inhibitor, 7 whereas erlotinib is metabolized by CYP3A4 8 ) and documenting any antitumor activity.
A standard 3 plus 3 dose escalation/deescalation design for phase I studies was used; the trial schema is shown in Supplementary Figure 1 . The study protocol was approved by the institutional review board at each clinical site. Patients with histologically proven, locally advanced/ metastatic (stage IIIB/IV) nonsquamous NSCLC who were aged 18 years or older, had progressed after one or two chemotherapy regimens for advanced disease, had an Eastern Cooperative Oncology Group performance status of 0 to 2, had measurable disease (defined by Response Evaluation Criteria in Solid Tumors, version 1.1), and had adequate organ function were eligible for inclusion in this study. Patients with brain metastasis were eligible if appropriately treated and neurologically stable for at least 4 weeks. No prior crizotinib or EGFR TKIs were allowed. A subsequent protocol amendment allowed patients with prior EGFR TKIs onto the phase I portion of the trial. Patients with interstitial lung fibrosis or interstitial lung disease were also excluded. All patients provided signed informed consent before study participation.
Treatment and Pharmacokinectic Evaluations
There was a 7-to 14-day lead-in period of erlotinib, once daily alone continuously, to determine the steadystate PK of erlotinib, which was evaluated on day À1 of cycle 1. The starting doses were crizotinib 200 mg twice daily, and erlotinib, 100 mg once daily (dose level 1). The starting dose of crizotinib was chosen to exceed the predicted level necessary for MET and anaplastic lymphoma kinase inhibition. 7, 9 The starting dose of erlotinib was chosen on the basis of the predicted effect of crizotinib on erlotinib exposure. 10 Crizotinib and erlotinib were then given concomitantly on a continuous schedule; cycle 1 was 28 days in length, and subsequent cycles were 21 days long.
Blood samples (3 mL) were collected at 0 (predose) and 0.5, 1, 2, 3, 4, 5, 6, 8, and 12 hours (for determining both crizotinib and erlotinib PK) and at 24 hours for determining erlotinib PK only after morning dosing on days 1 and 15 of cycle 1. PK parameters, including area under the concentration-time curve over the dosing interval (AUC s ), were obtained by noncompartmental analysis. The effect of continuous daily crizotinib dosing on erlotinib PK was evaluated by using the AUC s of erlotinib on both day 1 and day 15 of cycle 1.
Toxicity and Response Evaluation
Toxicities were graded using the Common Terminology Criteria for Adverse Events, version 4.0. Dose-limiting toxicities (DLTs) were defined as treatment-related grade 4 or higher hematologic toxicities (excluding lymphopenia in the absence of other DLTs), grade 3 or higher treatment-related febrile neutropenia, treatment-related grade 3 or higher nonhematologic toxicities, diagnosis of interstitial lung disease, or inability to receive at least 80% of the planned crizotinib or erlotinib doses during cycle 1 on account of possible treatment-related adverse events (AEs). All patients had an ophthalmologic examination at baseline, which was repeated during the study if clinically indicated. Response evaluation is described in Supplementary Methods.
Statistical Analysis
Patients who received at least one dose of crizotinib and erlotinib were included in the safety analysis for the combination period and were evaluated for antitumor activity (those who had an adequate baseline tumor assessment). The PK analysis was performed in patients who received at least one dose of the study drug and had at least one PK assessment.
Descriptive statistics were used to summarize safety, antitumor activity, and PK variables. To assess the effect of repeated crizotinib dosing on erlotinib PK, AUC s was log-transformed and analyzed using a mixed effects model with treatment as a fixed effect and patient as a random effect. The 90% confidence interval (CI) for the ratio of the geometric mean of AUC for crizotinib and erlotinib to erlotinib alone was calculated.
For the evaluation of a potential drug-drug interaction between crizotinib and erlotinib, a sample size of 16 patients provided more than an 80% probability that the 90% CI for the ratio of the AUC of crizotinib and erlotinib to erlotinib alone was within 0.8 to 2.15 if the true ratio was 1.5, assuming a level of intrapatient variability for the erlotinib AUC of 38.5%.
Results
Patient Characteristics
Between January 2010 and December 2011, 27 patients received at least one dose of erlotinib during the lead-in phase. Twenty-six patients received at least one dose of crizotinib and erlotinib. Baseline clinicopathologic characteristics are listed in Table 1 . At the time of the database snapshot (August 21, 2012), one patient (who withdrew from the study in January 2014 after disease progression in December 2013) was still receiving treatment (crizotinib, 150 mg twice daily, and erlotinib, 100 mg once daily). Data (duration of treatment and duration of response) from this last patient was captured in the database (locked on April 17, 2014) and included in this report. All other data in this manuscript were based on the database snapshot of August 21, 2012.
DLTs
Three patients had DLTs: grade 3 esophagitis (n ¼ 1) and dry eye (n ¼ 1) at dose level 1 and grade 2 esophagitis, dysphagia, and dyspepsia precluding receipt of at least 80% of the cycle 1 doses at dose level À1 (n ¼ 1). The MTDs were determined to be crizotinib, 150 mg twice daily, and erlotinib, 100 mg once daily. Enrollment was expanded to a total of 20 patients at the MTD. DLTs developed in two additional patients: grade 3 diarrhea and dehydration (n ¼ 1) and grade 2 vomiting that rendered the patient unable to receive 80% of the cycle 1 doses on a Pfizer Inc., data on file.
account of possible treatment-related AEs (n ¼ 1). All DLTs resolved after the study medication was stopped.
AEs (Combination Treatment)
All but one patient (96%) had at least one treatmentrelated AE during the combination treatment period; however, these were predominantly grade 1 or 2 in severity ( Table 2 ). There were no grade 4 or 5 treatment-related AEs.
PK Evaluations
At dose level À1 (crizotinib, 150 twice daily, and erlotinib, 100 mg once daily), the ratios of geometric means for erlotinib exposure (cycle 1, day 15) compared with erlotinib administered alone (cycle 1, day À1) were 149% (90% CI: 126-177) for AUC s (Fig. 1A) and 135% (90% CI: 115-157) for the maximum plasma concentration (C max ) ( Table 3 ). At dose level 1 (crizotinib, 200 twice daily, and erlotinib, 100 mg once daily), the ratios of geometric means for erlotinib exposure (cycle 1, day 15) compared with erlotinib administered alone (cycle 1, day À1) were 185% (90% CI:150-228) for AUC s (Fig. 1A) and 160% (90% CI: 121-212) for C max (Table 3) . Compared with historical PK data, crizotinib exposure appeared to be unaffected by coadministration with erlotinib (Fig. 1B) . 
Treatment Activity
Median duration of treatment with crizotinib and erlotinib in the combination period was 7 weeks for the overall patient cohort (n ¼ 26) (range <1 to 78 weeks). Twenty-five of the 26 patients who received at least one dose of crizotinib and erlotinib had a baseline assessment evaluable for antitumor activity (Table 4) .
A waterfall plot among the 20 response-evaluable patients reporting at least one follow-up scan is presented in Figure 2A . The treatment duration, best response, smoking status, and prior EGFR TKI treatment for each patient are shown in Figure 2B . Both patients who achieved a partial response had tumors with EGFR exon 19 deletion mutations. 
